What is the Need for Prostatic Biomarkers in Prostate Cancer Management?

Spahn, Martin; Boxler, Silvan; Joniau, Steven; Moschini, Marco; Tombal, Bertrand; Karnes, R Jeffrey (2015). What is the Need for Prostatic Biomarkers in Prostate Cancer Management? Current urology reports, 16(10), p. 70. Current Science 10.1007/s11934-015-0545-3

[img]
Preview
Text
art%3A10.1007%2Fs11934-015-0545-3.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (282kB) | Preview

Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Spahn, Martin and Boxler, Silvan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1527-2737

Publisher:

Current Science

Language:

English

Submitter:

Katharina Morgenegg

Date Deposited:

08 Feb 2016 16:12

Last Modified:

09 Nov 2016 08:59

Publisher DOI:

10.1007/s11934-015-0545-3

PubMed ID:

26267226

BORIS DOI:

10.7892/boris.75201

URI:

https://boris.unibe.ch/id/eprint/75201

Actions (login required)

Edit item Edit item
Provide Feedback